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3Abstract
On January 14, 2003, the Food and Drug Administration “suspended 27 gene therapy trials involving several
hundred patients after learning that a second child treated in France had developed a condition resembling
leukemia.”1 Gene therapy treats diseases caused by defective genes by introducing healthy genes into the
body. For patients who are battling life-threatening diseases, the only chance of survival may be the hope of
gene therapy, perhaps because there is no known cure, no available matched transplant donor, or no cures
without even worse side eﬀects. “Some of the trials being halted are intended to treat AIDS and cancer.”2
The “second child treated in France,” who caused the alarm, had received gene therapy treatment not for
AIDS or cancer, but for the less common ailment “bubble boy disease,” a severe and fatal immunodeﬁciency
disorder. Bubble boy disease attacks newborn boys, who while in the womb, relied on their mother’s
immunity but, once born, are left helpless in ﬁghting other diseases that attack their infant bodies. With
the trials halted, parents are left helpless to seek gene therapy for their children. Is it right to eliminate
alternate, but risky remedies?
1Andrew Pollack, “Gene Therapy Trials Halted,” The New York Times, January 15, 2003 at Health and at
http://www.newyorktimes.com/2003/01/15/health/15GENE.html.
2Id.
4I. Introduction
What is “bubble boy disease?” Bubble boy disease is the popular term for a condition that leaves a male child
without a working immune system. The child can rely on the immunity transferred to him from his mother
while in the womb, but once born, the immunity promptly wears oﬀ, leaving the child helpless against
disease. Although other immunodeﬁciency disorders as acquired immunodeﬁciency syndrome (“AIDS”)3
may be more notorious, bubble boys are ﬁghting the same deadly handicap. Since the child cannot depend
on a normal, healthy immune system to ﬁght oﬀ diseases, a common cold can quickly worsen into pneumonia
and be deadly. “Without an immune system, a patient is completely vulnerable to infection a pathogen
that would be harmless to a person with normal immunity would destroy a SCID patient.”4 Unfortunately,
unlike AIDS, there is no way to prevent this genetic disease, and left untreated, death is certain within two
years.5 Thus, it was the custom to isolate bubble boy patients in a plastic bubble to keep out germs.
Who are these bubble boys? Bubble boy disease is extremely rare, aﬀecting only 0.001 percent of children
at birth.6 Yet it is a death sentence without explanation. The only available treatment for these boys is
3This paper uses numerous acronyms. Although these acronyms are deﬁned repeatedly throughout the paper, a list of
acronyms used is attached at the end of this paper.
4“Early Marrow Transplant May be Key to ‘Bubble Boy’ Disease Cure,” Doctor’s Guide, May 5, 1997 at
http://www.pslgroup.com/dg/25666.htm.
5“FDA Places Temporary Halt on Gene Therapy Trials Using Retroviral Vectors in Blood Stem Cells,” FDA Talk Paper,
January 14, 2003 at http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01190.html (“Infants with X-SCID have a gene
defect that leads to a complete lack of white blood cells that can ﬁght infection. Without treatment, they die from complications
of infectious diseases during the ﬁrst year of life.”).
6“Homo Sapiens Diseases Immunity,” Molecular Immunology at http://xoomer.virgilio.it/medicine/pathohomotissueimmunity.html
(“severe combined immunodeﬁciency (SCID) / Swiss type agammaglobulinemia / ‘bubble boy disease / syndrome’ Epidemi-
ology : 1 in 75,000 live births (1 in 100,000 live male births).”). See also “New Cure For Bubble Boy Disease,” CBS News,
April 17, 2002 at http://www.cbsnews.com/stories/2002/04/17/tech/main506451.shtml (“The ﬁve French boys were born with
severe combined immunodeﬁciency, or SCID, an inherited disease that occurs in about 1 in 75,000 births.”).
5bone marrow transplants.7 Transplants require ﬁnding a matched and willing donor.8 Transplants have the
dangers associated with any surgical procedure.9 Transplants come with the deadly risk of incurring another
fatal disease, graft versus host disease (“GVHD”), a condition caused if the body reacts negatively to the
new transplant.10
While bone marrow transplants are the only available treatments, they are not the only known treatments.
In 2000, a miraculous new treatment using gene therapy, which is a method of treating genetic diseases
by introducing healthy genes into the body, cured bubble boy disease for the ﬁrst time.11 Gene therapy
7“FDA Places Temporary Halt on Gene Therapy Trials Using Retroviral Vectors in Blood Stem Cells,” FDA Talk Paper,
January 14, 2003 at http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01190.html (“The only treatment for this condition
is a bone marrow transplant.”). See also “Inherited (Congenital) Immune System Disorders,” The National Marrow Donor
Program at http://www.marrow.org/MEDICAL/immune sys disorders.html (“For almost all congenital immune system dis-
orders, however, the treatment of choice is a blood stem cell transplant.”).
8“Inherited (Congenital) Immune System Disorders,” The National Marrow Donor Program at
http://www.marrow.org/MEDICAL/immune sys disorders.html (“The main obstacle to a blood stem cell transplant is
lack of a matching donor. Doctors ﬁrst look for donors in a patient’s family, but only about one in four patients ﬁnd a match
in their own family.”). But see “Early Marrow Transplant May be Key to ‘Bubble Boy’ Disease Cure,” Doctor’s Guide, May
5, 1997 at http://www.pslgroup.com/dg/25666.htm (“They also have learned that these children need not have a perfectly
matched donor, but can use a parent’s ‘half-matched’ marrow.... ‘Until 1982, SCID was invariably fatal unless the patient had
a brother or sister who was an exact match to donate bone marrow,’ [Rebecca] Buckley [chief of Duke’s division of pediatric
allergy and immunology] explained. ‘What we see now is that a sibling match isn’t necessary; haploidentical parental marrow
will work, too.’ A haploid match is a half match.”).
9However, bubble boys no longer endure diﬃcult pre-transplant treatments to prepare the body for the transplant, including
radiation and chemotherapy. Compare “Early Marrow Transplant May be Key to ‘Bubble Boy’ Disease Cure,” Doctor’s
Guide, May 5, 1997 at http://www.pslgroup.com/dg/25666.htm (“Furthermore, the babies do not need toxic pre-transplant
chemotherapy, as is often thought and currently practiced.... [Rebecca] Buckley [chief of Duke’s division of pediatric al-
lergy and immunology] also found that transplants can be done without exposing the infant to toxic chemotherapy, which
can have life-long repercussions. Many doctors give chemotherapy to all bone marrow transplant patients because they are
following standard cancer treatment protocol, Buckley said. But chemotherapy is not necessary in children with SCID be-
cause they have no T-cells to attack and destroy the foreign donor marrow, as is the case with cancer patients. ‘Patients
with SCID have no immune systems to reject the transplants. Our approach avoids toxic agents and their possible compli-
cations,’ she said.”) with “Inherited (Congenital) Immune System Disorders,” The National Marrow Donor Program at
http://www.marrow.org/MEDICAL/immune sys disorders.html (“To prepare for a stem cell transplant, patients receive high
doses of chemotherapy and/or radiation therapy to destroy their immune systems... . The pre-transplant treatment can be
very hard on a patient’s body, and there is a risk of organ damage, including permanent sterility.”).
10“Inherited (Congenital) Immune System Disorders,” The National Marrow Donor Program at
http://www.marrow.org/MEDICAL/immune sys disorders.html (“In addition, the donated stem cells might attack the
patient’s body. This is called graft-versus-host disease (GVHD). If GVHD develops, doctors can treat it with drugs, but GVHD
still sometimes causes death after a stem cell transplant.”). But see “Early Marrow Transplant May be Key to ‘Bubble Boy’
Disease Cure,” Doctor’s Guide, May 5, 1997 at http://www.pslgroup.com/dg/25666.htm (“Moreover, [Rebecca] Buckley
[chief of Duke’s division of pediatric allergy and immunology] has found a way to reduce a potentially fatal complication
of transplants called graft-versus-host disease (GVHD). By removing the donor’s T-cells before the transplant, the donor’s
marrow cannot rise up and attack the patient’s vital organs – a common complication with bone marrow transplants. And, by
removing these cells before the transplant, the infant avoids the toxic drugs normally given to suppress the donor’s T-cells.”).
11See “Gene Therapy Cures ‘Bubble Boy,”’ New Scientist, April 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992124 (“Alain Fischer’s team at the Necker Hospital in Paris re-
6treatments of bubble boy disease promised almost perfect success rates, did not require any donor, and did
not come with the threat of a negative reaction to the treatment.12
However, there is a one in a hundred-thousand chance that any one transferred gene will integrate in the
gene that causes leukemia.13 Moreover, for gene therapy to have a high chance of successfully integrating
in the right gene, doctors introduce one million genes into the body.14 Although it usually takes multiple
genetic changes to cause leukemia, the number of genes introduced genes made leukemia a possibility.15 This
concern was only hypothetical until two children developed leukemia-like symptoms after undergoing gene
therapy treatment for bubble boy disease.16 The French, English, and American governments responded
to this occurrence and quickly halted the trials.17 Still, ﬁfteen patients – eleven boys in Paris and four
boys in London – were cured of bubble boy disease from gene therapy before the trials were halted.18 Now,
other patients, who were waiting to receive gene therapy treatments, face certain death, because this option
is no longer available. The fate of these patients spurs endless questions of public policy, constitutional
rights, and ethical dilemmas. This paper uncovers these questions and attempts to answer them in light
of the controversial January 14, 2003 decision of the Food and Drug Administration (“FDA”) to suspend
ported the ﬁrst-ever treatment in 2000.”).
12See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc (“There will be no more ‘bubble boys.”’).
13Andrew Pollack, “2nd Cancer is Attributed to Gene Used in French Test,” The New York Times, January 17, 2003 at
Health and at http://www.newyorktimes.com/2003/01/17/health/17GENE.html (“Dr. [Christof] von Kalle [a doctor at the
Cincinnati Children’s Hospital Medical Center and a collaborator with the French researchers] said the chance of a virus landing
on LMO-2 was about 1 in 100,0000.”).
14Id. (“But since each child was given about one million cells, the probability is very high that a child received at least one
cell in which the virus landed on the gene [that causes leukemia].”).
15Id. (“But Dr. von Kalle said scientists believed that turning on just one oncogene [a cancer-promoting gene] would not be
a problem because it usually requires multiple genetic changes to turn a cell cancerous.”).
16Id. (“In both cases, the gene inserted into the boys’ blood-forming stem cells landed on or near an oncogene, or
cancer-promoting gene, called LMO-2, which can spur childhood leukemia. In the ﬁrst case the gene landed inside LMO-
2 and the second landed near enough to turn on the gene, Dr. von Kalle said.”). See also Joshua J. Loomis, “X-
SCID Gene Therapy in France – An Undesirable Integration Event,” Viral Vectors as Mediators of Gene Therapy
at http://narnia.n.ml.org/skier/writings/doc/microm%20496.doc (noting that the LMO-2 gene on chromosome 11 has been
linked to leukemia).
17Andrew Pollack, “Gene Therapy Trials Halted,” The New York Times, January 15, 2003 at Health and at
http://www.newyorktimes.com/2003/01/15/health/15GENE.html.
18Id.
7twenty-seven “gene therapy trials involving several hundred patients.”19
The FDA decision to halt the trials clearly prevents more patients from contracting leukemia or another life-
threatening ailment through gene therapy treatments. Yet it simultaneously prevents these patients from
receiving a cure of diﬀerent fatal diseases, including bubble boy disease. The governmental decision to halt
the trials clearly protects an unaware public from undergoing a dangerous procedure. Yet it simultaneously
blocks well-informed parents from choosing the uncertain risks of gene therapy over the certain risks of
bubble boy disease for their beloved children. The governmental decree rescues parents from making very
diﬃcult decisions. Yet it robs them of their right, perhaps a constitutional right, to make those decisions.
The government’s growing paternal virtues may be a direct result of the American people hastily reacting in
anger, disappointment, and shock whenever a rare but highly publicized failure, especially one that results in
death, hits the news stands. The result for the American public is often the sought-after higher standards of
safety, but those higher standards mean fewer available choices. Less choice is sometimes better; the public
does not always have the resources to make risk-beneﬁt decisions for everyday incidents. Perhaps, this cycle
is useful in the majority of the FDA decisions covering everyday resolutions on food labeling, nonprescription
drugs, and truthful advertising.
However, bubble boy disease is far from an everyday incident, and the FDA decision is hardly an everyday
resolution. This paper analyzes whether the proper role of the FDA should be diﬀerent in rare life-threatening
situations than in everyday situations. In cases of uncommon fatal diseases, this paper determines that the
FDA should adopt less rigid regulations, allow for more personal autonomy, and grant alternative treatment
19Id.
8options despite a higher risk level involved. A governmental tolerance for high-risk treatments in cases of rare
fatal diseases actually makes legal, ﬁnancial, and ethical sense. Legally, this paper asserts that the United
States Constitution gives a dying person the right to choose a risky treatment that oﬀers the only chance at
survival. Financially, a person suﬀering from a rare disease is more likely to dedicate proportionally more
resources to the disease than the public. Ethically, the individual who will die if left untreated deserves
the opportunity of treatment, despite its risks, though the public would decide against the risk. This paper
discusses each of these reasons in detail below.
The United States Constitution limits the authority of the federal government in favor of individual power
on issues of privacy, self-dignity, and personal autonomy. For example, the famous case of Roe v. Wade20
stands for upholding rights to autonomy and privacy in making decisions over one’s body, following the
paths carved from Griswold v. Connecticut21 and Eisenstadt v. Baird.22 The well-known case of Cruzan
v. Director, Missouri Dep’t of Health23 held that every person has constitutional rights to life and dignity
in death. Finally, Maher v. Roe24 represents a case where the United States Supreme Court found a right
to medical treatment. These signiﬁcant constitutional cases represent individual rights, religious and philo-
sophical rights, and medical rights that state personhood, self-dignity, and life are critical considerations
under the U.S. Constitution.
Similar discussions surface in cases against the FDA speciﬁcally dealing with rare fatal diseases. For ex-
ample, during the AIDS revolution, AIDS patients fought for investigational new drugs (“IND”), which are
usually limited to clinical studies, to be available to non-clinical participants as treatment under certain
20Roe v. Wade, 410 U.S. 113 (1973).
21Griswold v. Connecticut, 381 U.S. 479 (1965).
22Eisenstadt v. Baird, 405 U.S. 438 (1972).
23Cruzan v. Director, Missouri Dep’t of Health, 497 U.S. 261 (1990).
24Maher v. Roe, 432 U.S. 464 (1977).
9conditions.25 Cancer patients also fought these ﬁghts, arguing that their constitutional rights of privacy
protected their right to use available, albeit not approved, drugs to treat their disease.26 On appeal, the
Tenth Circuit agreed and acknowledged the special case of these patients. The Tenth Circuit asked, “[W]hat
can ‘generally recognized’ as ‘safe and eﬀective’ mean as to such persons who are so fatally stricken with
a disease for which there is no known cure?”27 Admittedly, the law does not always side with this view,
and the Supreme Court unanimously reversed this decision by the Tenth Circuit, ﬁnding that there is “no
special provision for drugs used to treat terminally ill patients.”28 Nonetheless, the continuing AIDS and
cancer ﬁghts maintain that constitutional rights of privacy, self-dignity, and autonomy should allow patients
of rare, fatal diseases to choose more dangerous, and less certain treatments.29 This paper argues that these
same rights extend to riskier gene therapy treatments, as well.30 If there is not an available transplant-donor
match, a child inﬂicted with bubble boy disease will die. In that case, the United States Constitution and
common law guarantees that boy an autonomous right to make his personal and private decision among all
known treatments, regardless of risk, to best maintain his dignity and treasure his life.
Second, there is the practical consideration of limited resources. With everyday products, the public con-
sumption is widespread, and thus the FDA will concentrate its eﬀorts on those issues. Correspondingly,
2542 U.S.C. § 300cc-12 (requiring the FDA to encourage sponsors of clinical trials to make AIDS drugs available for treatment
purposes if there is preliminary evidence that the drug prevents or treats AIDS). See also Peter B. Hutt and Richard A. Merrill,
“The AIDS Revolution,” Food and Drug Law: Cases and Materials, Westbury, NY: The Foundation Press Inc (1991) at
552 (discussing the “revolution in the availability of investigational drugs to treat life-threatening diseases, in the early approval
of new drugs for these diseases”).
26Rutherford v. United States, 438 F. Supp. 1287 (W.D. Okl. 1977).
27Rutherford v. United States, 582 F.2d 1234, 1237 (10th Cir. 1978).
28Rutherford v. United States, 442 U.S. 544 (1979).
29Even the FDA recognized that it must make its decision in light of the fatal results of the disease. See “FDA Places
Temporary Halt on Gene Therapy Trials Using Retroviral Vectors in Blood Stem Cells,” FDA Talk Paper, January 14, 2003
at http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01190.html (“FDA’s continuing review of adverse event reports from
all U.S. studies involving retroviral vectors has to date found no evidence of leukemia caused by the gene therapy. Moreover,
the agency has to consider the potential risks of any experimental therapy within the context of the disease it may treat – in
this case a devastating disease in children.”).
30When the FDA placed the halt on gene therapy treatments, it made a similar statement, although it has failed to follow
through on its promise. See “FDA Places Temporary Halt on Gene Therapy Trials Using Retroviral Vectors in Blood Stem
Cells,” FDA Talk Paper, January 14, 2003 at http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01190.html (“FDA will
consider and evaluate speciﬁc requests for clinical indications for fatal or life-threatening disorders for which there are no viable
alternative treatments.”).
10the individual will devote few resources to learning more about each of these numerous trivial products.
Conversely, for rare diseases, the FDA will devote fewer resources, because it aﬀects a small percentage of
the public, but the inﬂicted individual will concentrate a great amount of resources on the singular and
relatively signiﬁcant disease. Therefore, limited resources dictate that the FDA or another public estab-
lishment is probably the best conductor of a risk-beneﬁt analysis in cases of everyday products.31 Yet the
individual is probably the best conductor of risk-beneﬁt analysis in cases of rare fatal diseases. The FDA
will proportionally devote fewer resources to bubble boy disease as compared to diseases that aﬀect more
children, while the parents of an inﬂicted child will devote almost a hundred percent of their resources to
understanding this disease. In light of this disparity of dedicated resources, the individual in the rare fatal
case of bubble boy disease should make the risk-beneﬁt decision regarding gene therapy. Although the risks
of gene therapy are high, allowing the individual to make this decision is the most sound approach, with
respect to both ﬁnances and time, design.
Finally, there is the unduly risk-averse characteristic of public organizations.32 News media have limited
resources of space, time, and money to inquire about current happenings. Consequently, mass media reports
failures, catastrophes, and errors more often than consistent performances, expected successes, and unencum-
bered results. Thus, the public perceives the risk of activities to be greater than in actuality, such as the risks
of a plane crashing, beef carrying mad cow disease, and earthquakes striking California.33 Consequently,
31See “Risk-Beneﬁt Analysis,” WUSTL, October 12, 1994 at http://capita.wustl.edu/ME567 Informatics/concepts/riskben.html
(“When individuals are exposed to involuntary risk, risk which they have no control, they make risk aversion their primary
goal. Under these circumstances individuals require the probability of risk to be as much as one thousand times smaller then
for the same situation under their perceived control.”).
32See id. (“Real future risk as disclosed by the fully matured future circumstances when they develop. Statistical risk, as
determined by currently available data, as measured actuarially for insurance premiums. Projected risk, as analytically based
on system models structured from historical studies. Perceived risk, as intuitively seen by individuals. Air transportation as
an example: Flight insurance company - statistical risk. Passenger - perceived risk. Federal Aviation Administration (FAA) –
projected risks.”).
33See id. (“Real future risk as disclosed by the fully matured future circumstances when they develop. Statistical risk, as
determined by currently available data, as measured actuarially for insurance premiums. Projected risk, as analytically based
on system models structured from historical studies. Perceived risk, as intuitively seen by individuals. Air transportation as
an example: Flight insurance company - statistical risk. Passenger - perceived risk. Federal Aviation Administration (FAA) –
projected risks.”).
11the public seeks greater insurance against these risks than suitable.34 As public servants, Congressional
representatives vying for reelection respond to these demands by directing administrative regulators, like the
FDA, to set higher than necessary standards to avoid these risks. The resultant, unduly risk-averse nature
of the FDA is desirable in an everyday setting, where the majority of individuals has risk-adverse preferences
and does not want to ascertain the risk for numerous trivial everyday purchases.35 However, this resultant
unduly risk-adverse nature is undesirable in rare fatal situations, where there is a higher chance that the
individual will prefer high-risk options, especially when those options oﬀer the only chance for survival.
“Doctors at Great Ormond Street say two UK patients have died in 2002, because they did not start gene
therapy in time.”36
This paper tells the full sad story of children suﬀering from bubble boy disease, the medical developments
of gene therapy, the promising trials that the FDA abruptly halted, and the standard FDA procedures that
threaten lives. The ﬁrst section of the paper introduces the medical developments of bubble boy disease,
exposing why the traditional treatment of bone marrow transplants is often impossible, inadequate, or
unusually lethal in itself for bubble boy patients. The paper then introduces the history of gene therapy,
illustrating the science of gene therapy treatments that use retroviruses, like in the bubble boy treatments,
to show why they have a higher risk. It then shares the complete history of the halted trials, from the
early successful results to the nervous apprehension after the ﬁrst boy contracted leukemia to the immediate
decision to suspend trials after the second child contracted leukemia.
34See id. (“Although many people feel that ﬂying is more risky than driving, statistics show otherwise. Perception of control
is a very important factor that explains why voluntary activities have risks of 100 to 1000 times greater than involuntary
activities.”).
35“The Theory of Risk Aversion,” New School at http://cepa.newschool.edu/het/essays/uncert/aversion.htm (“We ﬁrst
turn to the concept of univariate ‘risk aversion’ which, intuitively, implies that when facing choices with comparable returns,
agents tend chose the less-risky alternative, a construction we owe largely to Milton Friedman and Leonard J. Savage (1948).”).
36See “‘Miracle’ Gene Therapy Trial Halted,” New Scientist, October 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992878.
12After giving a vivid picture of the disease, the treatment options, and the FDA decision, the paper then
discusses the role of the FDA. The paper introduces the standard procedure of the FDA, and the manner
in which the FDA regulates gene therapy. The paper delves into the structure of the FDA, including its
relationship with the National Institutes of Health (“NIH”) in regulating bubble boy disease, gene therapy,
and clinical trials.
With a complete picture of the disease, the science, the treatment, and the regulator, the paper discusses
the legal and social consequences of the FDA decision to halt the gene therapy trials that promised to cure
bubble boy disease. On one hand, the FDA has a duty to protect the American people, and faces certain
liability for failure to live up to its duty. The American people demand that the FDA use its power to
avoid putting the American people in risk of peril. On the other hand, the Constitution upholds privacy,
autonomy, and self-dignity. Children suﬀering from bubble boy disease are facing imminent death unless
treated, and gene therapy is sometimes the only chance for life. The parents of these children are willing
to devote proportionally more resources to determine the individual risk-beneﬁt analysis for their child.
Furthermore, they are in the best position to understand if the risk is not a risk at all, because it has become
their last hope. This ﬁnal section of the paper discusses a way of achieving a proper balance between the
two competing and conﬂicting interests.
13II. The Science
A. The Disease
X-linked severe combined immunodeﬁciency (“X-SCID”)37 is the proper medical term, but “bubble boy
disease” evokes a remarkably accurate image of the condition aﬄicting only male children with such severe
immune system impairments at birth that they live in a bubble. During pregnancy, SCID infants carry the
immunity transferred to them from their mother, but once born, they gradually lose their defense against
infection. Without medical intervention, every single child plagued with SCID has an early death sentence.
“Most infants with severe combined immunodeﬁciency disease develop pneumonia, thrush, and diarrhea,
usually by age 3 months.”38 With a malfunctioning immune system, these serious infections progress into
conditions that are even more serious. “If not treated, these children usually die before age 2.”39
Although it aﬀects only one child in about 75,000 births, SCID appalls parents and doctors alike.40 “Severe
combined immunodeﬁciency disease is the most serious immunodeﬁciency disorder. It can be caused by
several diﬀerent genetic defects, most of which are hereditary.”41 Unfortunately, while scientists understand
37There are many diﬀerent forms of Severe Combined Immunodeﬁciency (“SCID”). This paper focuses on X-linked SCID
(“X-SCID”), the most common form of SCID, known also as bubble boy disease, because it aﬀects only male children. However,
ADA-SCID, which is SCID caused by the absence of the enzyme adenosine deaminase (“ADA”), another known form of SCID,
aﬀects both male and female children. In fact, ADA-SCID, although less famous, was identiﬁed much sooner, and was understood
almost immediately to be single-gene defect, which is easier to treat. Thus, treatments were available for ADA-SCID before
the causes of X-SCID were known. Indeed, at that time, X-SCID had not even been identiﬁed. This paper uses the terms
“X-SCID” and “bubble boy disease” interchangeably. This paper uses the term “SCID” to include all forms of SCID. When
referring to other forms of SCID, this paper identiﬁes it with a diﬀerent preﬁx, such as “ADA-SCID.”
38“Severe Combined Immunodeﬁciency Disease,” The Merck Manual – Second Home Edition at
http://www.merck.com/mrkshared/mmanual home2/sec16/ch184/ch184i.jsp.
39“Severe Combined Immunodeﬁciency Disease,” The Merck Manual – Second Home Edition at
http://www.merck.com/mrkshared/mmanual home2/sec16/ch184/ch184i.jsp.
40“Homo Sapiens Diseases Immunity,” Molecular Immunology at http://xoomer.virgilio.it/medicine/pathohomotissueimmunity.html
(“severe combined immunodeﬁciency (SCID) / Swiss type agammaglobulinemia / “bubble boy disease / syndrome” Epidemi-
ology : 1 in 75,000 live births (1 in 100,000 live male births)”). See also “New Cure For Bubble Boy Disease,” CBS News,
April 17, 2002 at http://www.cbsnews.com/stories/2002/04/17/tech/main506451.shtml (“The ﬁve French boys were born with
severe combined immunodeﬁciency, or SCID, an inherited disease that occurs in about 1 in 75,000 births.”).
41“Severe Combined Immunodeﬁciency Disease,” The Merck Manual – Second Home Edition at
14some of the diverse genetic origins of SCID well, other causes of SCID remain inexplicable. “The most
common type is linked to the X chromosome, making this form aﬀect only males. Other forms of SCID
usually follow an autosomal recessive inheritance pattern or are the result of spontaneous mutations. One of
these other forms is linked to a deﬁciency of the enzyme adenosine deaminase (ADA). Other cases of SCID
are caused by a variety of other defects.”42
X-SCID or bubble boy disease is the most common form of SCID, but scientists identiﬁed ADA-SCID in the
1970s, much earlier than X-SCID.43 ADA-SCID was recognized as a single-gene defect immediately.44 Long
before cloning and sequencing the gene, clinical studies showed that diﬀerent mutations in a single common
gene caused all the diﬀerent severity levels in ADA-SCID cases.45 Single-gene defects as opposed to multi-
gene defects are much easier to isolate and treat.46 Consequently, treatments for ADA-SCID were developed
much earlier than for X-SCID, despite X-SCID being the more prevalent form.47 Indeed, gene therapy for
ADA-SCID was one of the ﬁrst gene-therapy treatments available and led the way for the gene therapy
treatments for X-SCID discussed in this paper.48 Today, scientists have identiﬁed X-SCID as another single
gene defect, and have similarly isolated the X-SCID gene.49
Despite not understanding all the causes of bubble boy disease, the tragic signiﬁcance of the disease is
exceedingly clear. The children aﬀected with SCID possess immune systems that noticeably lack a distressing
amount of essential T cell and B cell functions, which are types of white blood cells and essential to the
http://www.merck.com/mrkshared/mmanual home2/sec16/ch184/ch184i.jsp.
42“Severe Combined Immunodeﬁciency,” The SCID Homepage at http://www.scid.net/.
43See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
44See id.
45See id.
46See id.
47See id.
48See id.
49See id.
15immune system.50 “This usually results in the onset of one or more serious infections within the ﬁrst few
months of life. These infections are usually serious, and may even be life threatening, they may include
pneumonia, meningitis or bloodstream infections.”51
When a normal, healthy immune system detects foreign adverse cells, it reacts in diﬀerent ways to defend
the body depending on the type of invasion.52 One critical way, the way that aﬀects bubble boys, involves
white blood cells that identify and destroy invaders.53 One type of these white blood cells, B cells, make
antibodies to mark foreign cells that other cells will attack.54 Meanwhile, another type of these white blood
cells, T cells, make strong chemicals to kill foreign cells.55 Thus, these B cells and T cells work together to
determine which cells are the bad cells, and then to attack and destroy them. Although there are other ways
for the immune system to defend the body, the low number and malfunction of T cells in SCID patients is
morbid to the body.
Ogden Bruton achieved the ﬁrst breakthrough in 1952 for the heart-breaking condition of these children,
when he discovered that there was an absence of certain proteins, critical to the immune system, in the
blood. Through this discovery, Bruton ﬁnally found an explanation for immunodeﬁciency, at least a general,
basic explanation. Since then, scientists have now identiﬁed over ﬁfty forms of genetically determined
50See “Gene Therapy Cures ‘Bubble Boy,”’ New Scientist, April 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992124 (“The faulty gene stops the development of T cells,
a key part of the immune system.”). See also “Severe Combined Immunodeﬁciency,” The SCID Homepage at
http://www.scid.net/ (“The deﬁning characteristic is usually a severe defect in both the T- & B-lymphocyte sys-
tems.”). See also “Inherited (Congenital) Immune System Disorders,” The National Marrow Donor Program at
http://www.marrow.org/MEDICAL/immune sys disorders.html (“SCID patients either have no B cells and T cells, or those
cells have severe defects. Several genetic defects can cause SCID, including not having enough of an enzyme called ADA
(adenosine deaminase) and having a defect in the gene that helps shape T cells.”).
51“Severe Combined Immunodeﬁciency,” The SCID Homepage at http://www.scid.net/.
52“Inherited (Congenital) Immune System Disorders,” The National Marrow Donor Program at
http://www.marrow.org/MEDICAL/immune sys disorders.html.
53See id. (“White blood cells called lymphocytes identify and destroy invaders.”).
54See id. (“One type of lymphocyte, a B cell, makes antibodies to mark foreign cells to be attacked.”).
55See id. (“Another type of lymphocyte, a T cell, makes strong chemicals to kill foreign cells.”).
16immunodeﬁciency diseases, including SCID, which is the most severe of them all. At ﬁrst, the only way
known to guard these children without normal immune systems to protect them, predominantly due to X-
SCID, was to make sure they were never exposed to any germs, so they never got any illnesses. “In the past,
children with this disorder were kept in strict isolation, sometimes in a plastic tent, leading to the disorder
being called ‘bubble boy syndrome.”’56 This plastic-tent life was hardly ideal, could not completely prevent
the children from getting sick, and did not protect the children from being doomed to an early death, but it
postponed the inevitable for a brief while.57
Then, in 1968, shortly after the discovery of a method to check for matches in transplants,58 some success
with bone marrow transplantation occurred in two patients with otherwise fatal immunodeﬁciency diseases.59
This critical discovery played a signiﬁcant role later in developing treatments for bubble boy disease, whose
causes remained unclear at this time. The two patients received transplants of matched60 bone marrow cells
from a matched donor, because bone marrow is a primary source of immune cells. Transplanting bone marrow
cells thus oﬀered the patients a new source of immunity. This milestone in SCID research demonstrated that
the defect in this immunodeﬁciency disease was not due to the failure of the marrow to support cell growth,
but instead to dysfunction in development of blood cell lines. Unfortunately, early marrow transplants
were marked with disappointments. Researchers learned that SCID patients were unusually, and extremely
susceptible to graft versus host disease (“GVHD”), a condition caused by the transplanted bone marrow
56“Severe Combined Immunodeﬁciency Disease,” The Merck Manual – Second Home Edition at
http://www.merck.com/mrkshared/mmanual home2/sec16/ch184/ch184i.jsp.
57See “Gene Therapy Cures ‘Bubble Boy,”’ New Scientist, April 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992124 (“Children must be kept in isolation to protect hem from
catching infections and usually die young.”).
58The discovery of HLA-antigens, certain proteins on cell surfaces that are important in identifying cross matches for trans-
plantation procedures, allowed for researchers to “match” transplant donors and recipients.
59“Severe Combined Immunodeﬁciency Disease,” The Merck Manual – Second Home Edition at
http://www.merck.com/mrkshared/mmanual home2/sec16/ch184/ch184i.jsp.
60By “matched,” the bone marrow cells had identical HLA-antigens. These “HLA-identical” bone marrow cells allowed
transplants to become a reality, instead of just a theory.
17T cells reacting against the patient. Hence, on top of the diﬃculty of ﬁnding a matched donor for a bone
marrow transplant to become even a possibility, there is the prone danger of SCID children facing an even
sooner end by contracting GVHD.
Amidst all these new medical understandings and developments, in 1971, David Vetter was born.61 David
is probably the most famous SCID case.62 He was the ﬁrst X-SCID patient given the name “bubble boy,”
who lived in isolation in a sterile plastic bubble with ﬁltered air for almost thirteen years, from his birth
in 1971 to his death in 1984.63 From his birth in Texas, David suﬀered from a genetic mutation leading to
SCID.64 He experienced human touch only once.65 Sadly, the attempt at treating David with a bone marrow
transplant from his older sister failed, because her tissue carried a virus that causes mononucleosis.66 After
the failed operation, David’s likelihood of survival disappeared, and David lived the remaining two weeks
of his life outside the bubble, dying before he was even a teenager.67 “SCID is often called ‘bubble boy
disease.’ SCID became widely known during the 1970’s and 80’s, when the world learned of David Vetter,
a boy with X-linked SCID, who lived for 12 years in a plastic, germ-free bubble.”68 It was the later Disney
ﬁlm rendition of David’s life that ensured the notoriety of David, the “bubble boy,” and increased public
awareness of bubble boy disease.69
Although the cause of immunodeﬁciency was discovered in 1952, a treatment using bone marrow transplants
for immunodeﬁciency was discovered in 1968, and David made the disease famous from his birth in 1971, the
61See “Severe Combined Immunodeﬁciency,” The SCID Homepage at http://www.scid.net/.
62See id.
63See id.
64See id.
65See id.
66See id.
67See id.
68Id.
69See id.
18disease was nameless until 1975. In 1975, John Soothill, M.D. suggested at the World Health Organization
Conference in Geneva that this syndrome should be called severe combined immunodeﬁciency, and it soon
acquired the acronym, SCID. Yet even then, the X-SCID gene remained unidentiﬁed, and far from being
isolated. Then, in 1990, before the X-SCID gene was identiﬁed, the gene therapy treatments for other forms
of SCID and for other diseases had already begun.70
Thus, gene therapy was never an option for David, because the gene, which when mutated causes X-SCID, the
form of SCID that aﬀected David, had not been identiﬁed even by 1990, let alone during David’s lifetime.71
Indeed, the biochemical nature of the defect causing X-SCID was not even known.72 Furthermore, there
was no known protein that would have allowed working backward to isolate the gene.73 As previously
mentioned, X-SCID is genetically distinct from ADA-SCID which, at the time, was a better understood
form of SCID, and the ADA-SCID gene had been identiﬁed and isolated.74 Even as late as 1990, when gene
therapy treatments were available for other diseases,75 including ADA-SCID, identiﬁcation of the X-SCID
gene seemed unattainable in the near future.76
The isolation and cloning of the X-SCID gene occurred sooner than expected, two years later.77 Then,
Japanese researchers in a completely unrelated project published their results in “Science’ after ﬁnding,
isolating, and sequencing the protein that would allow working backward to isolate the X-SCID gene.78 Just
70See W. French Anderson, “Human Gene Therapy,” 392 Nature 25, 25-30 (1998), also at
http://www.frenchanderson.org/docarticles/pdf/humangenetherapy 0498.PDF.
71See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
72See id.
73See id.
74See id.
75See W. French Anderson, “Human Gene Therapy,” 392 Nature 25, 25-30 (1998), also at
http://www.frenchanderson.org/docarticles/pdf/humangenetherapy 0498.PDF.
76See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
77See id.
78See id.
19two years earlier, such a discovery seemed impossible, but this unconnected research hastened the discov-
ery.79
In early research, scientists searched for the chromosomal location of the X-SCID gene by studying how
the gene segregates families aﬀected with X-SCID.80 Obviously, the researchers noticed immediately that
X-SCID only aﬀected males, and from this observation, deducted that the general chromosomal association
was the X chromosome.81 Any further understanding of the X-SCID gene location on the X chromosome
emerged very slowly, because the rarity of X-SCID meant there were very few families available for study of
X-SCID carriers.82 Furthermore, sadly, X-SCID infected boys did not survive long enough for an inclusive
research.83 Finally, comparison of the inheritance pattern of the X-SCID gene with better known X chromo-
somal functions narrowed its location to a smaller region of DNA, but still one that was too large to isolate,
clone, or sequence.84
Meanwhile, though, Japanese researchers, in an unrelated project having nothing to do with X-SCID, were
studying the structure of a molecule found on the surface of T cells.85 T cells make and release a small
hormone-like molecule which other cells consume to help them respond to an infection.86 Remarkably and
surprisingly, T cells themselves consume the same molecule that they produce.87 During a response to a
particular immune challenge, T cells release this molecule into their immediate vicinity, and then consume
some of the molecule they had just released to produce more of their own kind to ﬁght the infection.88
The T cell receptor, allowing them to grab this hormone-like molecule, initially was thought to consist of
79See id.
80See id.
81See “Gene Therapy Cures ‘Bubble Boy,”’ New Scientist, April 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992124 (“The disease aﬀects boys because they only have one X
chromosome.”).
82See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
83See id.
84See id.
85See id.
86See id.
87See id.
88See id.
20two diﬀerent protein chains.89 Yet certain aspects of the receptor’s function seemed inconsistent with this
two-protein model.90 The researchers were studying the T cell to explain the disparity in the theory.91 From
their research, they found that there was indeed a third protein chain.92 The Japanese researchers then
isolated and sequenced the protein, and promptly published their discovery.93
This description and characterization of the receptor’s newly discovered third protein chain explained many
of the puzzles relating to the molecule’s function.94 Using this information, a research team at the National
Institutes of Health (“NIH”) made the connection of this protein with X-SCID.95 The NIH researchers showed
that the protein bound only to the X chromosome, speciﬁcally to one location.96 The NIH researchers further
showed that the DNA from every X-SCID patient sampled had mutation in a gene of the third protein.97
There were no mutations in any of the normal individuals sampled.98 Thus, it became clear that the gene of
the third protein was the gene that, in mutant form, causes X-SCID.99 “Boys with X-SCID (severe combined
immunodeﬁciency) have a faulty copy of a gene on their X chromosome that makes an immune protein called
interleukin-2. As a result, they have no resistance to infection and die unless treated.”100
From this information, in late 1992, scientists isolated the X-SCID gene, and through the known characteris-
tics of the third protein, understood the exact cause of X-SCID.101 Children inﬂicted with X-SCID have the
hormone-like molecule to ﬁght oﬀ disease, but the malfunctioning third protein prevents them from being
able to grab the molecule and properly function. Consequently, the T cells do not perform correctly, and
89See id.
90See id.
91See id.
92See id.
93See id.
94See id.
95See id.
96See id.
97See id.
98See id.
99See id.
100See “‘Miracle’ Gene Therapy Trial Halted,” New Scientist, October 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992878.
101See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
21X-SCID children are left with virtually no immune protection. However, clinical experiments with a perfect
third-protein gene inserted into a retroviral vector showed that this gene can be delivered to bone marrow
cells and B cells. These gene therapy treatments promised that there would never be another bubble boy. At
this point, the science behind the disease begins to merge with the science behind the treatments, especially
gene therapy.
22B. The Treatment
Despite the endless discussions marveling at the breakthrough of gene therapy, the FDA has not approved
a single gene therapy for general use.102 Thus, not one human gene-therapy product is for sale. The
possibilities of gene therapy began its promise of miracles for fatally ill patients as early as the 1960s.103
Yet the FDA refuses to approve gene therapy treatments beyond an experimental phase where individual
patients are given a chance at life on a case by case basis. Thus, many people die waiting for their chance
at a miracle. Since the halt of the twenty-seven gene therapy trials on January 14, 2003, even fewer patients
have a chance at a miracle. Admittedly, while gene therapy may suggest a non-intrusive remedy similar
to psychological care, it is an imperfect, dangerous, and precise procedure with multifaceted consequences.
Gene therapy techniques can correct defective genes responsible for disease development, but can also mutate
healthy genes causing new and diﬀerent diseases.104
For boys aﬀected with bubble boy disease, gene therapy is sometimes the only treatment available. “Treat-
ment with antibiotics and immune globulin is helpful. The best treatment is transplantation of stem cells
from bone marrow or umbilical cord blood.”105 However, as discussed above, bone marrow transplants are
102See “Cellular and Gene Therapy,” Center for Biologics Evaluation and Research at
http://www.fda.gov/cber/gene.htm (“FDA has not yet approved any human gene therapy product for sale.”).
103See W. French Anderson, “Human Gene Therapy: The Initial Concepts,” Gene Therapy for Diseases of the Lung,
Brigham, K.L., eds.: Marcel Dekker, Inc. (1997) at 3-16, also at http://www.frenchanderson.org/docarticles/pdf/hgt initial.pdf
(“However,
as early as 1963 Lederberg wrote in an article ‘Biological Future of Man’: We might anticipate the in vitro culture of germ
cells and such manipulations as the interchange of chromosomes and segments. The ultimate application of molecular biology
would be the direct control of nucleotide sequences in human chromosomes, coupled with recognition, selection and integration
of the desired genes...”). See also “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials
for ADA-SCID at http://www.wrclarkbooks.com/downloads/healers chapter.doc (“The possibilities for applying the emerging
techniques of molecular biology to human gene therapy were appreciated by a handful of people as early as the late 1960s.”).
104These risks particularly emerge in retroviral gene therapy, which uses a type of virus, called a retrovirus, to infect the
defective cell and introduce the properly functioning gene. The retroviral can infect many types of cells, besides the defective
cell, and can cause serious complications, including death. Thus, retroviral gene therapy, which is used to treat bubble boy
disease, entails a much higher risk than other types of gene therapy, and all the gene therapy trials halted by the FDA on
January 14, 2003 involved retroviral gene therapy treatments. Retroviruses, the retroviral gene therapy technique, and the risks
associated with this technique are discussed in this paper.
105“Severe Combined Immunodeﬁciency Disease,” The Merck Manual – Second Home Edition at
23not always an available or a safe option. Even if transplants and antibiotics were an option for a high
percentage, it remains that there are boys without this option. “Gene therapy seems to be eﬀective in some
infants who have one form of severe combined immunodeﬁciency disease. Gene therapy consists of removing
some white blood cells from the infant, inserting a normal gene into the cells, and returning the cells to the
infant.”106
There are many gene therapy approaches, using diﬀerent methods to introduce healthy genes into the body,
each with diﬀerent types of risks. In the most common gene-therapy procedure, researchers insert a normal
gene into the body to replace a nonfunctional gene. A second distinct method swaps an abnormal gene for a
normal gene. A third method repairs the abnormal gene through reverse-mutation to returns the gene to its
normal function. A fourth method alters the strength of the abnormal gene to prevent it from functioning
at all.
The idea is simple but the actualization is much more complicated. These methods require using viruses
to invade the body, but with healthy genes instead of sickly genes. These viruses serve as viral vectors in
the gene therapy treatment to direct the healthy genes to diﬀerent locations in the body. The danger of
using viral vectors is that they create additional complications, including the risk of viral infection. However,
non-viral vectors, as an alternative to viral vectors, while presenting fewer complications, are thus far much
less eﬃcient at introducing the healthy genes into the body.
There are four classes of viruses used in gene therapy treatments. One class of viruses, adenoviruses, have
double-stranded DNA genomes that typically cause respiratory, intestinal, and eye infections in humans, like
the virus that causes the common cold. Adenoviral vectors target a wide range of cells, allowing for a high
probability of eﬀectiveness. Yet adenoviral vectors are non-integrating, which means they do not incorporate
http://www.merck.com/mrkshared/mmanual home2/sec16/ch184/ch184i.jsp.
106Id.
24themselves into the body permanently, and must be reintroduced repeatedly to treat gene therapy patients.
Another class of virus used in gene therapy treatments, adeno-associated viruses, are small, single-stranded
DNA viruses that can insert their genetic material only at one ﬁxed chromosomal location, making them
nonrealistic options for many gene therapy patients. A third class of viruses, herpes-simplex viruses, like
the virus that causes cold sores, are double-stranded DNA viruses that also can only infect a particular cell
type, neurons, similarly making them less valuable in gene therapy treatments. Unfortunately, none of these
classes of viruses can be used to treat bubble boy disease.
The class of viruses used in treating bubble boy disease is retroviruses, which create double-stranded DNA
copies of their genomes that can be integrated into the chromosomes of host cells very eﬀectively. A familiar
retrovirus, namely the human immunodeﬁciency virus (“HIV”), more commonly referred to by its acronym,
reveals the menacing characteristics of this virus.107 The quality that allows HIV to incorporate itself quickly
in the body, threatening fatal and permanent damage to the immune system, makes retroviral vectors very
good at integrating with the body to deliver healthy genes for long-term, ideally permanent, remedies. Yet
retroviruses, like adenoviruses, can integrate into a wide range of cells, increasing their utility in gene therapy
treatments, but also increasing the risk of infecting the wrong cell, since they randomly integrate, sometimes
in regions where they should not. “Gene therapy involved shuttling the gene into a patient’s cells using a
harmless virus. But transferred genes cannot be targeted to insert into a speciﬁc part of the chromosome.”108
This characteristic explains the reason the gene therapy treatment that cured the two children may have
integrated into the gene that causes leukemia. Furthermore, retroviruses, unlike adenoviruses, can integrate
permanently, promising a permanent cure while threatening permanent damage. Finally, retroviruses only
infect rapidly dividing cells, which increases the chance that the treatment will have quick results. However,
107See W. French Anderson, “Human Gene Therapy,” 392 Nature 25, 25-30 (1998), also at
http://www.frenchanderson.org/docarticles/pdf/humangenetherapy 0498.PDF.
108See “‘Miracle’ Gene Therapy Trial Halted,” New Scientist, October 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992878.
25this characteristic also speciﬁcally increases the risk of leukemia, a disease where blood cells proliferate out
of control, since the gene that causes leukemia is a rapidly dividing gene.
Scientists began isolating and sequencing proteins since the 1950s. With the complete amino acid sequence
of a protein and using the genetic code, it is possible to work backwards and predict the sequence of the
corresponding gene.109 However, individual genes could not yet be isolated, and thus gene therapy remained
only a theoretical possibility. Yet the dream of gene therapy grew with the breakthrough of the 1960s,
when physician and scientist Stanﬁeld Rogers observed that viruses could deliver genes, one of the founding
blocks to modern gene therapy.110 Rogers was using rabbits to study one of the genes carried by a common
wart-causing virus.111 This gene encodes a certain enzyme that degrades excess amount of an amino acid, a
building block of protein, as discussed above.112 In rabbits infected with this virus, the levels of this amino
acid in the blood were unusually low.113 Then, upon removing blood samples from people in the laboratory,
Rogers found that laboratory personnel handling the infected rabbits had become infected with the virus, not
an uncommon occurrence in the laboratory.114 The critical ﬁnding, however, was that these people also had
extremely low levels of this amino acid.115 This ﬁnding proved that genes carried as part of a viral genome
could alter normal physiological processes in a human being.116 Thus, viruses could theoretically deliver
genes to diﬀerent cells in the human body.117 Of course, at this point, human genes had never been isolated,
and thus gene therapy remained only an idea, but the possibilities for applying the emerging techniques of
molecular biology to human gene therapy were born. Subsequently, in 1967, Marshall Nirenberg, the Nobel
109See Peter B. Hutt and Richard A. Merrill, “Regulation of Biotechnology,” Food and Drug Law: Cases and Materials,
Westbury, NY: The Foundation Press Inc (1991) at 964-985 (noting that the James Watson and Francis Crick discovery of
1953, the double-helix structure of DNA, opened the ﬁeld of molecular biology and led to the possibility of gene therapy).
110See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
111See id.
112See id
113See id
114See id
115See id
116See id
117See id
26Prize winner, wrote of programming cells with synthetic messages, making the subject of gene therapy into
an ethical debate.118
In the 1970s, isolating individual genes became a possibility.119 Thus, the theoretical advances discussed
above, from knowing the complete amino acid sequences of quite a few proteins, came together and made
isolating genes a reality.120 In 1977, the ﬁrst human gene, part of the oxygen-carrying molecule of red blood
cells, was isolated and cloned.121 Defects in this gene can cause diseases like severe anemia,122 which is the
inability to make red blood cells and is life-threatening.123 Subsequently, a physician at UCLA, Dr. Martin
Cline, working with another UCLA scientist, tried introducing the gene into mouse bone marrow cells using
a viral vector.124 The experiment worked.125 More importantly, when the altered bone marrow cells were
put back into mice, there was evidence that they survived and that the added gene was functioning.126 The
researchers then applied to their university’s Human Subjects Protection Committee, an institutional review
board (“IRB”), for permission to try the same thing in human patients with severe anemia.127 Unable to
get permission from UCLA, Cline recruited patients suﬀering from this condition in foreign institutions.128
Several patients had samples of their bone marrow removed, exposed to the vector containing the healthy
118See John C. Fletcher, “Evolution of Ethical Debate About Gene Therapy,” 1 Human Genet Therapy 55, 55-60 (Spring
1990) (tracing the development of gene therapy from the beginnings by Nobelist Marshall Nirenberg).
119See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
120See id
121See LeRoy Walters, “Ethical Issues in Human Gene Therapy,” 2 Journal of Clinical Ethics 267, 267-274 (Winter 1991)
(discussing the unauthorized experiment of Martin Cline after hemoglobin, the gene in red blood cells responsible for carrying
oxygen to the entire body was isolated).
122This disease discussed here is thalassemia, which is a genetic blood disorder when the body can not make enough hemoglobin,
a part of the red blood cells that carries oxygen to all of the body. Thalassemia is one of the most serious forms of anemia,
which is the more general disorder describing an absence of functioning red blood cells.
123See LeRoy Walters, “Ethical Issues in Human Gene Therapy,” 2 Journal of Clinical Ethics 267, 267-274 (Winter 1991)
(discussing the unauthorized experiment of Martin Cline).
124See id
125See id
126See id.
127See id.
128See id.
27gene, and then infused back into their bloodstream.129 The experiment failed to alter the course of their
disease, but the patients appeared to suﬀer no harm from the procedure either.130 His institution, the
federal government, and the international scientiﬁc community denounced Martin severely.131 Thus, the
ﬁrst attempt at gene therapy using cloned DNA destroyed hopes with the poor results and the negative
response from the community. Nonetheless, the research continued.
In 1983, three separate laboratories published the gene sequence encoding ADA, one of the earlier human
genes to be isolated and cloned for study, and the malfunction of which causes ADA-SCID.132 In the late
summer of 1990, the NIH Recombinant DNA Research Advisory Committee (“RAC”), working with the
FDA, and the FDA ﬁnally were suﬃciently convinced by the preliminary laboratory data to approve the
ﬁrst human gene therapy trial.133 Thus, in 1990, National Institutes of Health (“NIH”) doctors conducted
the ﬁrst clinical trial of gene therapy.134 It succeeded.135 A four-year-old girl named Ashanti DeSilva received
genetically altered cells to ﬁx a rare condition she had inherited at birth.136 That rare condition happened
to be a form of SCID, although ADA-SCID, not X-SCID.137 DeSilva had been in advanced stages of her
disease, and standard therapies were not working.138
Before ﬁnal FDA approval had been obtained for the entire gene therapy procedure, samples of T cells were
collected from DeSilva’s blood and infected with the ADA vector in vitro.139 The cells were ﬁrst triggered to
start dividing, in order to enhance penetration by the retroviral vector.140 After exposure to the virus, the
129See id.
130See id.
131See id.
132See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
133See id.
134See id.
135See id.
136See id.
137See id.
138See id.
139See id.
140See id.
28cells were grown in an incubator for about a week to expand their total numbers.141 Final FDA approval
was received on the morning of September 14, 1990.142 In that afternoon, four-year-old DeSilva was infused
with her own T cells containing the retroviral ADA vector, and became the ﬁrst human being in history to
undergo gene therapy for therapeutic purposes.143
The procedure went smoothly.144 Her white blood cells received a gene that makes an immune system
protein, the third protein of a T cell, that she lacked.145 The genetically treated white blood cells perform
for only a few months, because the T cells do not live very long unless stimulated from ﬁghting oﬀ foreign
cells.146 Thus, the eﬀect is only transient, because the gene therapy treatment for ADA-SCID transforms the
T cells.147 However, stimulated T cells become long-lived “memory” T cells, and these previously generated
memory cells normally handle most of an immune response.148 Over time, a SCID patient in whom even a
small proportion of T cells were kept alive long enough to be stimulated might build up a repertoire of T cells
capable of responding to most types of foreign cells.149 This situation describes the prognosis for DeSilva.150
For a while, she had to continue to receive gene therapy on a regular basis.151 After four infusions over
a four-month period, DeSilva’s T cell counts were climbing toward normal. Direct analysis of DeSilva’s T
cells showed that nearly all of them expressed the newly inserted ADA gene.152 Today, DeSilva is relatively
healthy, lives a normal life, and no longer receives gene therapy treatments of infusions of gene-altered T
cells.153 DeSilva’s daily existence illustrates the hope of gene therapy attained, and explains the ceaseless
141See id.
142See id.
143See id.
144See id.
145See id.
146See id.
147See id.
148See id.
149See id.
150See id.
151See id.
152See id.
153DeSilva is now 17 years old and is considered a success story for gene therapy. See “Gene Therapy Turns 10,” Current
Science, January 19, 2001 at http://www.ﬁndarticles.com/cf dls/m0BFU/10 86/69527187/p1/article.jhtml.
29hope for those, like “bubble boys,” to try this treatment as well.
One of the conditions imposed by the Recombinant DNA Research Advisory Committee (“RAC”) was that
DeSilva and subsequent patients receiving ADA-SCID gene therapy continue taking PEG-ADA.154 PEG-
ADA is a drug, ADA protein, which had been approved by the FDA as a standard treatment for ADA-SCID
in 1990, just shortly before the Recombinant DNA Research Advisory Committee (“RAC”) approved ADA
gene therapy.155 In many children, PEG-ADA causes a marked initial increase in the number of T cells,
alleviating many of the complications of ADA-SCID.156 On the other hand, some children gain little or no
sustainable beneﬁt after a few administrations of the ADA drug, and it is enormously expensive, more than
two hundred thousand dollars per year for the average patient.157 PEG-ADA does not correct the underlying
defect, but simply alleviates its symptoms, and thus must be taken regularly for the life of the patient.158
DeSilva was being treated with PEG-ADA at the time she began gene therapy. Although she did not seem
to be responding to the drug, it was considered inappropriate to discontinue its use.159 Hence, evaluation of
gene therapy in its ﬁrst and longest lasting trial is complicated by the continued administration of a drug
with the same potential eﬀect of gene therapy, an increase in viable T cells.160
Some investigators feel that the PEG-ADA may actually be working against the eﬀectiveness of the under-
lying gene therapy treatment.161 PEG-ADA helps keep all T cells alive, whether or not they are malfunc-
tioning.162 From a gene therapist’s point of view, PEG-ADA is helping “bad” as well as “good” T cells
154See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
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30to survive.163 There is reason to believe that, in the absence of PEG-ADA, those T cells infected with a
healthy ADA gene would have a selective advantage for survival, and would eventually outgrow and displace
the malfunctioning T cells.164 However, they were unable to convince the RAC and FDA to allow them to
wean DeSilva or other patients oﬀ the PEG-ADA in order to ﬁnd out.165
In September 1999, gene therapy suﬀered a major setback with the ﬁrst death from gene therapy, eighteen-
year-old Jesse Gelsinger, an otherwise relatively healthy patient.166 Gelsinger was participating in a gene
therapy trial for a metabolic disorder.167 A severe negative immune response to the high dose of an early-
generation adenoviral vector caused multiple organ failures, including failure of the liver, kidney, and lungs.
Four days after starting the treatment, Gelsinger passed away. Following Gelsinger’s death, government of-
ﬁcials investigated the treatment and found that gene therapy researchers were careless with patient safety,
and were even neglecting to report deaths.168 Gelsinger’s death resulted in decreased clinical participation,
tighter regulations, and more obstacles for researchers.169 Nonetheless, gene therapy persevered, albeit a bit
more slowly.170
163See id.
164See id.
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166See Sally Lehrman, “Virus Treatment Questioned After Gene Therapy Death,” 401 Nature 517, 517-18 (October 7, 2001)
and at http://www.nature.com/cgi-taf/DynaPage.taf?ﬁle=/nature/journal/v401/n6753/full/401517b0 fs.html (discussing the
setback of gene therapy after Gelsinger’s death).
167See Joan Stephenson, “Studies Illuminate Cause of Fatal Reaction in Gene-Therapy Trial,” 285 JAMA: The Journal of
the American Medical Association 2570 (May 23-30, 2001) and at http://jama.ama-assn.org/cgi/content/full/285/20/2570
(discussing the cause of Gelsinger’s death eight months later).
168See United States Congress, Senate, Committee on Health, Education, Labor and Pensions, Subcommittee on Public
Health, “Gene Therapy: Is There Oversight for Patient Safety?: Public Hearing,” Washington, D.C.: Unpublished testimonies
and documents from the hearing, 69 pages (February 2, 2000) (featuring testimony from Gelsinger’s father, gene therapy
patients, and medical experts).
169Id. See also Alfred J. Smuskiewicz, “Genetic Medicine Update,” World Book, 2001 at
http://home.earthlink.net/∼ajjsart/genmedwb.html (“Gelsinger’s death triggered action by federal health authorities to
strengthen monitoring and regulation of gene therapy experiments in the United States. In March 2000, the FDA and the
U.S. National Institutes of Health (NIH) announced that they planned to conduct more unscheduled inspections of gene
therapy facilities and maintain greater oversight of gene therapy experiments. The agencies also said they would provide more
information to scientists and the public.”).
170See Trisha Gura, “After a Setback, Gene Therapy Progresses... Gingerly,” 291 Science 1692, 1692-1697 (March 2, 2001)
and at http://www.sciencemag.org/cgi/content/full/291/5509/1692 (discussing the slow progression of gene therapy treatment
for hemophilia in light of Gelsinger’s death).
31III. The Regulator
A. The FDA and the NIH
The curt story of the science behind bubble boy disease is depressing at best. Bubble boy disease destroys
the immune system, insuring a very early death if left untreated. The available treatments are limited mostly
to bone marrow transplants, which require a matched donor and come with the high risk of graft versus
host disease (“GVHD”), which is also fatal. Gene therapy trials were extremely promising, curing every boy
treated, but alas had diﬀerent risks. Furthermore, the FDA has since halted all the trials after two of the
ﬁfteen boys treated developed leukemia-like symptoms.
Thus, the dismal future of the bubble boys reduces to the connected and much more complicated story of the
FDA, whose far-reaching, well established, and strong authoritative role began with a congressional mandate.
The FDA, a part of the Department of Health and Human Services since 1979, obtains its authority under
the Federal Food, Drug, and Cosmetic Act of 1938.171 “Authorized by Congress to enforce the Federal
Food, Drug, and Cosmetic Act and several other public health laws, the agency monitors the manufacture,
import, transport, storage, and sale of $1 trillion worth of goods annually, at a cost to taxpayers of about
$3 a person.”172 Congress, however, could not have known the questions the FDA faces today. The FDA’s
objectives, guidelines, and procedures determine the decisions that allow some treatments but not others,
including those decisions that aﬀect babies ﬁghting for their lives against bubble boy disease.
171See Peter B. Hutt and Richard A. Merrill, “The Federal Food, Drug, and Cosmetic Act of 1938,” Food and Drug Law:
Cases and Materials, Westbury, NY: The Foundation Press Inc (1991) at 6. See also “Frequently Asked Questions,” U.S.
Food and Drug Administration at http://www.fda.gov/opacom/faqs/faqs.html (noting the 1979 amendment to the 1938 Act
in 93 Stat. 668, 695 (1979)).
172See “Designation and Locations of FDA in Federal Government,” U.S. Food and Drug Administration at
http://www.fda.gov/opacom/morechoices/designat.html.
32In 1974, the National Institutes of Health (“NIH”) began regulating recombinant DNA research.173 The
Recombinant DNA Research Advisory Committee (“RAC”) to the NIH Director was also created at this
time.174 The RAC approves all research projects involving recombinant DNA in laboratories in the United
States, handles gene-marking research, and reviews all gene therapy trials with the FDA.175 In other words,
the RAC oversees all federally funded research involving recombinant DNA.176 The intrusion of the RAC
into clinical trials involving recombinant DNA grew out of a deﬁning moment in the history of molecular
biology.177
Scientists began making recombinant DNA molecules almost as soon as it became possible in the 1970s.
The initial experiments ﬁgured out only the conditions necessary for cutting and stitching together pieces of
DNA from various sources in test tubes. Before long, scientists were eager to move on to more interesting
and practical possibilities. Thus, some scientists began carrying out experiments involving intact genomes
removed from bacteria and viruses.
In 1973, Herb Boyer and Stanley Cohen created the ﬁrst biologically functional recombinant DNA molecule.
They had placed a toad gene into bacteria. The bacteria promptly began making the corresponding toad
protein. Scientists closely followed the new, widely known experiments with recombinant DNA, and started
to get nervous. No one had ever before tampered with the genome of a living organism. There was no
evidence that such experiments were in fact dangerous, but the suggestion was made that all the scientists
involved should suspend further experimentation until the community had a discussion.
173See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
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33The meeting to discuss the implications and possible risks of recombining the DNA of living organisms took
place at the Asilomar Conference Center near Monterey, California, in 1974.178 All of the major laboratories
working with recombinant DNA attended, along with representatives of the federal agencies funding this
research.179 Out of this meeting came a proposal to ask the prestigious National Academy of Sciences to
establish a committee to review the current status of recombinant DNA technology.180 This committee
would also advise the government whether and how to regulate such research using this technology. The
committee ultimately recommended that the NIH permanently establish the RAC, which the NIH formed
almost immediately.181 Over the next two years, the RAC began formulating guidelines for carrying out
recombinant DNA research funded by federal research grants.182 NIH published these guidelines in 1976.183
Almost immediately, virtually all laboratories in the United States carrying out such research, however
funded, adopted the guidelines.184 Indeed, most governments throughout the world also eventually adopted
the guidelines in one form or another.185
The early workings of the RAC dealt almost exclusively with safety issues for laboratory research.186 The
major concern initially was that altered life forms would escape from laboratories and infect plants, animals,
or people on the outside.187 RAC, in responding to this concern, disseminated guidelines for “containment”
procedures, handling and storage of recombinant DNA, and other practical issues, to research laboratories
throughout the country.188 Institutions sponsoring such research were required to establish institutional
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34review boards (“IRB”) to ensure implementation of the RAC guidelines, and to assure that all applications
for government research funding submitted to NIH met RAC standards.189 Mindful of the furor that had
attended the earlier forays in the direction of human gene therapy, the RAC also established a permanent
Human Gene Therapy Subcommittee.190 This subcommittee took on the task of carrying out initial reviews
of all research involving human genes, whether intended for therapeutic purposes or not.191 The government
later decided that any proposals to introduce DNA into human beings would also be subject to clinical
trials as deﬁned by the FDA.192 Thus, for the time being, both the RAC and the FDA approved clinical
trials for gene therapy.193 When gene therapy moved out of the laboratory and into humans, there was a
move on the part of some biotechnology companies and a few academics to have the RAC abolished, and to
transfer sole authority for approving clinical trials to the FDA.194 However, the unique role the RAC plays
in assessing the quality and value of the basic science underlying and likely to emerge from clinical trials was
a considerable value.195
In 1996, the review of individual gene-therapy protocols became the sole responsibility of the FDA. However,
the RAC continues to review protocols that involve new technologies, and to recommend regulatory changes
based on evolving techniques. The FDA oversees the safety and eﬃcacy of the genetically altered products,
the safety of the manufacturing process, and control of the ﬁnal product. Within the FDA, the Center
for Biologics Evaluation and Research (“CBER”) regulates gene therapy. “CBER is the Center within the
FDA responsible for ensuring the safety and eﬃcacy of blood and blood products, vaccines, allergenics, and
biological therapeutics. CBER’s regulation of biological products has expanded in recent years to include
a wide variety of new products such as biotechnology products, somatic cell therapy and gene therapy, and
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35banked human tissues.”196 Gene therapy, as a biologic, is subject to the regulations under the Public Service
Health Act, as well as the Federal Food, Drug, and Cosmetic Act. “Biologics have been predominantly
regulated under the Public Health Service Act although they are also deﬁned as drugs under the Food
Drug and Cosmetic Act.”197 Gene therapy thus endures an extraordinarily diﬃcult review process. “Gene
transfer clinical trials have a unique oversight process administered by the National Institutes of Health
(NIH), through the Recombinant DNA Advisory Committee (RAC) and the NIH Guidelines for Research
Involving Recombinant DNA molecules, and the Food and Drug Administration (FDA) through review and
approval of gene therapy protocols and premarket approval requirements for gene therapy products.”198
196See “Frequently Asked Questions,” Center for Biologics Evaluation and Research at
http://www.fda.gov/cber/faq.htm.
197See id.
198See “Gene Transfer,” Genetics and Public Policy Center at http://www.dnapolicy.org/genetics/transfer.jhmtl;$sessionid$4I4DCIQAACY4WCQBAT#RVQQ.
36B. The Trials
Before the FDA became involved a few decades ago in 1962, clinical trials were generally informally organized
studies carried out by physicians, usually in collaboration with drug companies, to test a new drug, medical
device or clinical procedure.199 These studies were often not standardized, lacked important controls, and
did not pay attention to proper statistical analysis of data.200 Consequently, many clinical trials produced
data of little real value.201 Yet patients were put at risk during such trials, and patients subsequently treated
by drugs or devices approved for general use as a result of faulty clinical trials were unknowingly also at
risk.202
Starting in the 1970s, the federal government began formulating speciﬁc sets of guidelines for clinical trials.203
Today, all new drugs and invasive medical devices are subject to rigorously controlled clinical tests before
being available for general clinical use.204 Clinical trials in the United States are overseen by the FDA, and
the FDA has ﬁnal authority for approving a new drug or invasive medical device for manufacture, marketing,
and general use by the medical community at large.205 Clinical trials are most often carried out in university
medical centers under the guidance of physicians who also have strong basic science backgrounds, or have
basic science consultants as part of the overall clinical trial team.206 In most cases, a potential manufacturer
or marketer of a new drug or procedure will be an active partner in clinical trials, providing the drug itself
and any other materials needed for the trials, and generally underwriting their costs.207
As discussed above, one of the major RAC guidelines is that all institutions sponsoring clinical trials must
199See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
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37have an internal institutional review board (“IRB”) to review clinical trial proposals before they are even
submitted for FDA approval.208 The IRB, sometimes called the Human Subjects Protection Committee,
carries out an initial assessment of the scientiﬁc soundness of the proposal, and makes certain that the data
collection and analysis procedures are valid and meaningful.209 Furthermore, the IRB determines that the
proposed patient population is appropriate for the aims of the trial, and that the proposal follows the proper
patient informed consent procedures.210 Similarly, all gene therapy treatments fall under these same clinical
procedures.211
Before a clinical trial can begin, the FDA must see compelling evidence from laboratory studies that a
proposed new drug or procedure is safe in animal and in vitro studies.212 This preclinical phase of testing
generally involves laboratory experiments with human cells grown outside the body, to gain insight into
potential toxicity and to be sure that the drug will be safe for humans.213 The next step is to test the drug
or procedure in animals.214 This work often begins with rats and mice, for reasons of economy and because
of the large backlog of experience with these animals and knowledge of how their physiology compares
with humans.215 A very useful animal model that ﬁnds increasing use in drug testing is the so-called nude
mouse.216 Nude mice have a genetic defect that prevents them from immunologically rejecting human cells
and tissues.217 A closely linked defect prevents them from developing fur, hence the “nude” designation.218
It is thus possible to transplant into nude mice a small piece of the human tissue a new drug is supposed
to aﬀect, to inject that drug into the mice, and to monitor the drug’s eﬀect on the human tissue.219 In
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38some cases, it may be appropriate to test the drug further on a larger animal before testing in humans, but
increasingly the nude mouse model has been able to satisfy federal regulators.220
Ultimately, of course, any new drug or procedure must be tested on human beings to be absolutely certain
it is safe and has the eﬀect intended by its developers.221 The FDA has developed very strict guidelines
for conducting human clinical trials.222 The ﬁrst principle of any clinical trial is fully informed consent of
the human subjects who will participate in the trial.223 Patients must clearly understand the experimental
nature of the procedures they will undergo, the possible dangers they may face, and the uses of the gathered
information.224 Researchers cannot mislead patients about beneﬁts to their underlying disease, or risks of
the treatment.225 Researchers must assure conﬁdentiality of the patient information.226 The FDA must
review a copy of information provided to each patient as part of the overall approval process for any new
clinical trial.227
Most clinical trials proceed in four phases.228 The FDA reviews each phase while it proceeds, and each phase
must be completed and approved before the next phase can begin.229 Although the exact description of each
phase may be slightly diﬀerent for each new drug or procedure, the following general guidelines apply to the
majority of trials conducted.230 In the ﬁrst phase, investigators look at how long the drug remains in the
system.231 The FDA observes whether its properties change once it is inside a human body, and whether it
causes any measurable side eﬀects, either as reported by the subject or as detected in laboratory tests.232
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39The ﬁrst phase usually tests a range of dosages that are guided by earlier toxicity tests on animals.233
Sometimes the ﬁrst phase tests infected persons, and sometimes the ﬁrst phase tests healthy volunteers.234
When ﬁrst phase tests the drug on infected persons, the patients are usually battling advanced stages of the
disease and have failed to respond to standard current therapies for the disease.235 The number of patients
involved in this ﬁrst phase is particularly few, no more than the number required to get preliminary data for
the points under study.236 Thus, at this phase, typically less than ten individuals have a chance to receive
the treatment.237
During the second phase, investigators focus on the eﬀectiveness of the new treatment.238 Dosage and
toxicity limits derived from the ﬁrst phase are used to design the larger-scale second phase trials to begin
assessing the value of the new drug or treatment as compared to existing treatments.239 The second phase
may test patients with less advanced stages of disease.240 Investigators continue to monitor patients closely
for toxicity and any side eﬀects.241 In this second phase, a larger numbers of patients are usually involved,
up to a few hundred individuals.242
At the third phase, larger numbers of patients, up to thousands of individuals, are tested in a variety of clinical
settings, including community hospitals, university medical centers, and private facilities.243 Additional data
on the interaction of the new drug with existing drugs used to treat the disease are gathered.244 Information
gathered in the third phase will eventually be used to instruct physicians about use of the new drug.245
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40Toxicity is still closely monitored.246 The drug developer will usually apply for formal approval from the
FDA to market the new drug after successful conclusion of the third phase of clinical trials.247
The fourth and ﬁnal phase of clinical trials occurs after the drug is approved by the FDA, and is required
to continue studying the eﬀects of the drug after general release.248 In this fourth phase, the drug may
be extended to slightly diﬀerent patient populations than those studied in earlier trials, or dosages may be
altered, or the drug tested in combinations with other previously-approved drugs.249 The drug may also be
extended for use in related conditions not speciﬁed in the original trials.250
Clinical trials test new products before allowing them to be sold publicly.251 Thus, these strict and time-
consuming phases are often very important to produce sound, scientiﬁcally meaningful information about
proposed new drugs, devices, or procedures, and protect the patients involved in the trials.252 They represent
the transition phase between highly promising basic laboratory research on a new drug or treatment method,
and the general release of that drug or treatment to the larger medical community for use in standard
therapy.253 Thus, clinical trials represent a riskier choice rather than waiting for FDA approval.254
However, others view these phases as overly rigid and risk-averse, especially in dealing with life-threatening
diseases and patients who have no hope to still be alive when the treatments are ﬁnally approved. For
instance, scores after discovering the promise of gene therapy,255 decades after perfecting the science,256 and
years after testing on nude mice,257 human gene therapy was ﬁnally ready just to begin the clinical trial
246See id.
247See id.
248See id.
249See id.
250See id.
251See id.
252See id.
253See id.
254See id.
255See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc (“The possibilities for applying the emerging techniques of
molecular biology to human gene therapy were appreciated by a handful of people as early as the late 1960s.”).
256See id. (“ By 1987 Anderson had prepared an initial proposal for clinical trials using the cloned human ADA gene to treat
patients with ADA-SCID.”).
257Indeed, there were expectations that clinical trials for gene therapy of X-SCID would be underway in the
41process. However, by this time, ﬁfty years later, many bubble boys had died. Furthermore, gene therapy
introduced some new complications and concerns that scared the FDA into making the approval process
even more diﬃcult than it had been in the past. Thus, clinical trials often represent the only chance at a
cure, when waiting means certain death.
It was this later situation in the trials that cured bubble boy disease for ﬁfteen children, four in London
and eleven in Paris.258 The treatment had been permissible in France since 2000.259 The gene therapy
treatment for bubble boy disease involves using retroviruses to insert the healthy genes into blood stem
cells to direct them to the T cells. The known risk of this particular method was that the retrovirus would
transfer the gene to other cells as well, resulting in a disease causing mutation.260 Leukemia, the disease
contracted by two of the children treated with gene therapy for bubble boy disease, is where the blood cells,
which naturally proliferate, proliferate out of control due to a mutation of the gene. Nonetheless, the serious
eﬀects of leukemia should not overshadow the fact that both these boys were successfully cured of bubble
boy disease, which would have killed them within a couple years if left untreated. Furthermore, the other
thirteen bubble boys treated with gene therapy beneﬁted from the procedure without developing leukemia.
In August 2002, it did not actually come as a surprise to the doctors, the government, or the parents when a
United States by 1997, but was delayed until at least three years and not in America, but instead in France.
See “Gene Therapy: The First Halting Steps,” The Journey Begins: The Clinical Trials for ADA-SCID at
http://www.wrclarkbooks.com/downloads/healers chapter.doc.
258See “‘Miracle’ Gene Therapy Trial Halted,” New Scientist, October 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992878 (“A total of 15 patients, have been treated so far – 11 in
Paris and four in London.”). See also “Gene Therapy Causes Cancer in Mice,” New Scientist, April 18, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992186 (“So far, around 400 patients have received gene therapy in the
UK alone, but only a few were treated with retroviruses. They include two ‘bubble babies’ otherwise condemned to living
forever in germ-free ‘bubbles’ because their immune systems do not work.”).
259See “‘Miracle’ Gene Therapy Trial Halted,” New Scientist, October 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992878 (“In 2000, a team lead by Alain Fisher at Necker Hospital,
Paris, carried out the ﬁrst gene therapy treatment, which replaced the faulty gene.”).
260See “Gene Transfer,” Genetics and Public Policy Center at http://www.dnapolicy.org/genetics/transfer.jhmtl;$sessionid$4I4DCIQAACY4WCQBAT#RVQQ
(“Thus, a signiﬁcant concern with gene transfer is that the introduced gene will integrate in the genome and cause interruption
or disruption of other gene functions, causing mutation and possibly disease. This was considered a largely hypothetical
concern until the recent occurrence of leukemia in a child who had gene transfer to treat a severe immune deﬁciency. While
the transferred gene appeared to function and alleviate the immune deﬁciency, the appearance of the leukemia may have been
due to the insertion of the transferred gene in yet another gene resulting in a disease causing mutation.”).
42child successfully treated for X-SCID with gene therapy developed leukemia. However, in response, France
promptly halted the trials there as the FDA allowed the trials to continue in the United States.261 Then,
in January 2003, a second child treated in a French gene therapy trial developed a leukemia-like condition.
Again, however, researchers anticipated this unfortunate consequence as a side eﬀect from the science. The
FDA immediately halted all gene therapy trials using retroviral vectors in blood stem cells as a response.
At the time, there were two hundred gene-therapy trials under way, with sixty trials involving retroviruses,
and twenty-seven trials using retroviruses to insert the genes into blood stem cells. Thus, the halted trials
only represented ﬁfteen percent of the gene therapy trials at the time. Yet, for the people aﬀected by these
ﬁfteen percent of trials, the FDA decision is deadly harsh, overly risk-averse, and unfairly dictatorial.
At the end of February 2003, the FDA’s Biological Response Modiﬁers Advisory Committee (“BRMAC”)
met to discuss possible measures that could allow a number of retroviral gene therapy trials for treatment of
life-threatening diseases to proceed with appropriate safeguards. The BRMAC recommended guidelines that
would increase the beneﬁt to risk ratio signiﬁcantly. For instance, the BRMAC would deny gene therapy
to X-SCID patients who had another treatment option, i.e., who had found matched262 donors for marrow
transplants. The BRMAC would permit X-SCID patients to undergo gene therapy if they could not ﬁnd a
matched donor, if their matched transplantation failed, and if their circumstances were otherwise so dire that
gene therapy was the only remaining option. These recommendations would make gene therapy available
only as a last recourse. However, today it is not available at all, because the FDA, over a year later, has
not yet acted on the BRMAC recommendations from this meeting.263 The January 14, 2003 FDA decision
261See “Miracle Gene Therapy Trial Halted,” New Scientist, October 3, 2002 at
http://www.newscientist.com/news/news.jsp?id=ns99992878 (“A ‘miracle’ gene therapy treatment for children suﬀering
from the fatal ‘bubble boy’ disease has been halted in France, after one of the patients developed leukemia as a direct
consequence of the treatment.”).
262By “matched,” the donor had HLA-identical bone marrow cells as the patient. HLA-identical means that the cell surfaces
had the same HLA-antigens.
263See “Gene Therapy,” Human Genome Project Information at http://www.ornl.gov/sci/techresources/Human Genome/medicine/genetherapy.shtml
(noting that as of December 9, 2003, the “FDA had not yet to make a decision based on the discussions and ad-
vice of the BRMAC meeting”). See also “CBER Talkpapers,” Center for Biologics Evaluation and Research at
http://www.fda.gov/cber/talkpapers.htm (noting the FDA decision to halt the trials on January 14, 2003, and the BRMAC
43to halt gene therapy trials, although aﬀecting a very small percentage of the American population, calls
the entire role of the FDA into question as overly risk-averse and authoritarian. Indeed, its own BRMAC
recommended that the FDA allow gene therapy options in certain cases. The FDA’s refusal to act upon
these recommendations in one way or another, and thus take responsibility for its decision, instead of evading
liability for the boys who die waiting for the FDA, is shameful.
meeting on February 28, 2003, but without any update on the matter through March 26, 2004).
44IV. The Society
A. The Rights
The NIH established the Recombinant DNA Research Advisory Committee (“RAC”), and the FDA estab-
lished the Center for Biologics Evaluation and Research (“CBER”), both to regulate gene therapy. Thus,
gene therapy ended up being regulated twice, by two diﬀerent federal organizations, and then within those
two organizations, two separate committees that focused on gene therapy. Evidently, gene therapy deserves
twice the scrutiny than any other treatment, despite the fact that gene therapy oﬀers the only hope for many
patients. Hence, the sad truth of the science working against bubble boy patients only becomes worse by
the rigid FDA regulations working against bubble boy treatments.
Gene therapy passed multiple FDA tests before it even reached the human clinical trials that the FDA halted
on January 14, 2003. As discussed earlier, leukemia was a known risk before the X-SCID gene therapy began
trials. Nonetheless, the two cases of boys cured of X-SCID who developed leukemia-like symptoms still
caused the FDA to halt the treatments responsible for the cure. The disease is deadly, but the FDA faces
a duty to protect the American public. These two realities work against each other. Children are dying
and parents are willing to do anything to save them. Children suﬀering from bubble boy disease are facing
imminent death unless treated, and gene therapy is sometimes the only chance for life. Therapies are far from
well understood and the FDA avoids the risks of the unknown. These conﬂicting interests are important,
and yet at complete odds. Amongst these life and death decisions when each decision risks death, and no
decision guarantees life, where do the rights of the parties involved lie?
45The United States Supreme Court has found that the Constitution guarantees a right to privacy. In Griswold
v. Connecticut,264 the Supreme Court noted, “The association of people is not mentioned in the Constitution,
nor in the Bill of Rights. The right to educate a child in a school of the parents’ choice – whether public or
private or parochial – is also not mentioned. Nor is the right to study any particular subject or any foreign
language. Yet the First Amendment has been construed to include certain of those rights.”265 The Supreme
Court found that “the First Amendment has a penumbra where privacy is protected from governmental
intrusion.”266 In applying this penumbra to aﬃrm the privacy of marriage, the Court stated, “We deal
with a privacy older than the bill of rights.”267 This same statement applies to the privacy of life, self-
preservation, and medical treatment, which is even older than the institution of marriage. The Griswold
Court stated, “The foregoing cases suggest that speciﬁc guarantees in the Bill of Rights have penumbras,
formed by emanations from those guarantees that help give them life and substance. Various guarantees
create zones of privacy.”268 No other right is more fundamental than the right to life. No other penumbra
can give more life to this right than the right to medical treatment. The zone of privacy this right creates
is the privacy to choose the medical treatment of gene therapy when there are no other treatment options.
In Eisenstadt v. Baird,269 the Court aﬃrmed this right of privacy found in Griswold. The Eisenstadt Court
stated, “If the right of privacy means anything, it is the right of the individual, married or single, to be free
from unwarranted governmental intrusion into matters so fundamentally aﬀecting a person as the decision
whether to bear or beget a child.”270 Similarly, the matter of gene therapy treatment, as a matter of life
versus death, fundamentally aﬀects an X-SCID patient.
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46The Supreme Court reaﬃrmed this right to privacy in Roe v. Wade.271 The Roe Court stated, “The
Constitution does not explicitly mention any right of privacy. [But] the Court has recognized that a right of
personal privacy, or a guarantee of certain areas or zones of privacy, does exist under the Constitution.”272
The Court has held that this right to privacy allows one to control one’s own body. In Roe, the Court
found that this right extends to abortion, “because until the end of the ﬁrst trimester mortality in abortion
is less than mortality in normal childbirth.”273 This analysis is particularly analogous to the gene therapy
discussion, where the mortality of X-SCID patients is much higher without the right to this treatment than
if this treatment were available. Both abortion and gene therapy are procedures that protect one’s mortality,
but one is a rightful, undeniable choice, and one is an unlawful unavailable choice. Peculiarly, it is the choice
that is unneeded by the availability of contraception that is legal, where the choice that is needed by the
inescapable nature of genetic disorders is illegal. Peculiarly, the choice that, without, may come with a
higher risk of mortality is legal, where the choice that, without, guarantees mortality, is illegal.
In deciding Roe, the Court noted, “This right of privacy, whether it be founded in the Fourteenth Amend-
ment’s concept of personal liberty [as] we feel it is, [or] in the [Ninth Amendment], is broad enough to
encompass a woman’s decision whether or not to terminate her pregnancy. The detriment that the State
would impose upon the pregnant woman by denying this choice altogether is apparent. Speciﬁc and direct
harm medically diagnosable even in early pregnancy may be [involved].”274 Again, this statement can easily
include gene therapy, where the speciﬁc harm that the government imposes with the halted trials is un-
deniable: boys die. The Court upheld “Roe’s essential holding”275 in Planned Parenthood of Southeastern
271Roe v. Wade, 410 U.S. 113 (1973).
272Id.
273Id.
274Roe v. Wade, 410 U.S. 113 (1973).
275Planned Parenthood of Southeastern Penn. v. Casey, 505 U.S. 838 (1992).
47Penn. v. Casey.276 The Court there stated, “[It] is tempting, as a means of curbing the discretion of federal
judges, to suppose that liberty encompasses no more than those rights already guaranteed to the individual
against federal interference by the express provisions of the ﬁrst eight amendments to the Constitution. But
of course this Court has never accepted that view.”277 The Court noted, “It is a promise of the Constitution
that there is a realm of personal liberty which the government may not enter.”278 The Court then resolved,
“[It] is settled now, as it was when the Court heard arguments in Roe, that the Constitution places limits
on a State’s right to interfere with a person’s most basic decisions about family and parenthood, as well as
bodily integrity.”279
The Supreme Court has also found a right to liberty, similar to the right of privacy, which also allows one
to control one’s own body. For instance, Cruzan v. Director, Missouri Dep’t of Health280 held the right to
liberty guaranteed the right to refuse medical treatment, even if the treatment would be life-saving and to
refuse it would be life-threatening. The Court has found Cruzan to hold, “The Due Process Clause guarantees
more than fair process, and the ‘liberty’ it protects includes more than the absence of physical restraint.
[The] Clause also provides heightened protection against government interference with certain fundamental
rights and liberty interests.”281 Along with Maher v. Roe,282 where the Court found a right to medical
treatment, the Court’s ﬁnding of rights to privacy, autonomy, personhood, liberty, life, and dignity support
276Id.
277Id.
278Id.
279Id.
280Cruzan v. Director, Missouri Dep’t of Health, 497 U.S. 261 (1990) (ﬁnding, inter alia, that a person can refuse medical
treatment eve if that refusal will cause death). “But when still a vibrant person Nancy had once remarked that she did not
want to live ‘as a vegetable.”’ Id. “[The] principle that a competent person has a constitutionally protected liberty interest
in refusing unwanted medical treatment may be inferred from our prior decisions.” Id. See also Vacco v. Quill, 521 U.S. 793
(1997) (noting that “[e]veryone, regardless of physical condition, is entitled, if competent, to refuse unwanted lifesaving medical
treatment”); Washington v. Glucksberg, 521 U.S. 702 (1997) (citing Cruzan as support that “the Due Process Clause protects
the traditional right to refuse unwanted lifesaving medical treatment”).
281Washington v. Glucksberg, 521 U.S. 702 (1997).
282Maher v. Roe, 432 U.S. 464 (1977) (upholding, inter alia, Connecticut’s use of Medicaid funds to reimburse women for the
costs of medically necessary, including for reasons of mental health, abortions).
48a Constitutional right to gene therapy when there are no other options. The Roe Court held, “[Where] certain
‘fundamental rights’ are involved, the Court has held that regulation limiting these rights may be justiﬁed
only by a ‘compelling state interest,” and that legislative enactments must be narrowly drawn to express
only the legitimate state interests at stake.”283 What is the compelling state interest in denying medical
treatment, in denying control over one’s own body, in denying the right to privacy, in the FDA decision that
denies the option of gene therapy? Although overruled by the Supreme Court, the Tenth Circuit made a
powerful argument, “[W]hat can ‘generally recognized’ as ‘safe and eﬀective’ mean as to such persons who are
so fatally stricken with a disease for which there is no known cure?”284 The concern of the Supreme Court
in overruling this decision was in ﬁnding that there is “no special provision for drugs used to treat terminally
ill patients.”285 However, these patients are not arguing for a special right for terminally ill patients any
more than abortion gives a special right for pregnant women or the right to refuse medical treatment gives a
special right for those in need of medical treatment. Instead, the Supreme Court should view it as a right for
all to choose riskier treatments when death is imminent and there are no alternate treatments. Furthermore,
the Tenth Circuit decision articulates that the compelling state interest in protecting human life,286 and in
thus prohibiting life-threatening treatments, cannot be applied to a person whose only chance of survival is
the life-threatening treatment.
283Roe v. Wade, 410 U.S. 113 (1973).
284Rutherford v. United States, 582 F.2d 1234, 1237 (10th Cir. 1978).
285Rutherford v. United States, 442 U.S. 544 (1979).
286See, e.g., Roe v. Wade, 410 U.S. 113 (1973) (“We repeat, however, that the State does have an important and legitimate
interest in preserving and protecting the health of the pregnant woman [and] that it has still another important and legitimate
interest in protecting the potentiality of human life.”).
49B. The Lives
The FDA admittedly has a congressional mandate to regulate gene therapy and to protect the American
public. However, the proper interpretation of this mandate must be diﬀerent in cases involving rare life-
threatening diseases. Under the Supreme Court rulings above, the FDA should adopt less rigid regulations,
allow for greater personal autonomy by permitting high-risk treatment options when there are no other
options, and the disease is fatal. A governmental tolerance for high-risk treatments in cases of X-SCID
makes legal, ﬁnancial, and ethical sense, since the United States Constitution guarantees individual liberty,
the resources of the FDA are limited, and the alternative for these children is only death.
The FDA mandate should include a duty to protect American rights, as well as American lives. Thus, in
fatal diseases, especially where there are no other options, the FDA regulations must be more ﬂexible, to
acknowledge that the compelling state interest of protecting life changes in those cases. The FDA mandate
should include a duty to inform and educate patients to help patients make their constitutionally protected
choice. The FDA mandate would continue to include a duty to protect lives. For high-risk treatments
of life-threatening diseases, the FDA could require that the patients sign a contract that binds patients
and waives claims for damages.287 In the case of X-SCID gene therapy treatments, the FDA could adopt
the standards recommended by the Biological Response Modiﬁers Advisory Committee (“BRMAC”). The
FDA could limit potential gene therapy candidates to patients who do not have a donor match for a bone
marrow transplant, have a high likelihood of contracting graft versus host disease (“GVHD”), or have had
an unsuccessful transplant.
287This option is not currently available under the Investigation New Drug (“IND”) process for drugs that are currently in
the clinical trial phase that treat fatal diseases.
50Finally, the FDA could focus more, especially with bubble boy disease, on early diagnosis. “‘This once-
fatal disease should be now seen as a pediatric emergency, a condition that needs immediate diagnosis and
treatment,’ says Dr. Rebecca Buckley, chief of Duke’s division of pediatric allergy and immunology.”288
SCID patients would have a higher chance of survival with an early diagnosis, before the disease reached
advanced stages. “The transplant needs to be done before the onset of opportunistic infection, she explained,
and in the ﬁrst few weeks of the baby’s life, when the donor marrow takes hold quickest. Waiting until after
the ﬁrst four weeks of life increases the risk of infection, as well as slowing the development of immunity from
the donor transplant.”289 Indeed, researchers recommend testing newborn babies, because even a month-old
baby has an increased risk in the transplant than a newborn. “Early diagnosis of SCID is rare because
doctors do not routinely perform a test in newborns to count white blood cells. Such a blood test could pick
up children with SCID as well as those with other serious immune deﬁciencies that would not be apparent
until the child developed an infection.”290 Doctors argue for early diagnosis to give more time to ﬁnd a
matched transplant donor, to have a chance to do the transplant while the child is still healthy, and to allow
for less costly procedures. “‘A simple blood test could allow us to treat, and most likely cure, SCID in an
infant at a reasonable cost. If found later, less eﬀective treatment can run into the millions.’ Buckley states,
‘What we’re saying is that essentially every baby with SCID could be cured if diagnosed early enough. SCID
should be considered a pediatric emergency.”’ 291
288“Early Marrow Transplant May be Key to ‘Bubble Boy’ Disease Cure,” Doctor’s Guide, May 5, 1997 at
http://www.pslgroup.com/dg/25666.htm.
289Id.
290Id.
291Id.
51V. Conclusion
In conclusion, the American public has a legal right to choose the best treatment for life-threatening diseases
when there are no available risk-free treatments and there is a guarantee of an early death without any
treatment. In the case of rare fatal diseases, the individual patient is in the best position to research
options, and make decisions based upon those options. The overly risk-averse nature of the FDA may
violate constitutional rights and American values.
The FDA can implement less rigid regulations for high-risk treatments involving life-threatening diseases
without threatening its authority in protecting the American public. Although the FDA cannot be responsi-
ble for the risks of gene therapy when those risks are well understood, the FDA can bind patients who choose
risky procedures. These contracts could include clauses that waive the patient’s rights to ﬁle a claim later
against the hospitals, doctors, and researchers for liability or damages.292 Furthermore, the FDA could limit
potential gene-therapy candidates to patients who do not have a donor match for a bone marrow transplant,
or have a high likelihood of contracting graft versus host disease (“GVHD”).
American values cherish individual freedoms of privacy, human dignity, and autonomy. Thus, it is imperative
for the FDA to change its standard procedures to fall in line with those values. In an eﬀort to protect society
from itself, the rolling wheels of the legal system too often enact paternal laws that conﬂict with these values.
Unfortunately, while American may possess a model system, it still fails to check and balance laws as quickly
as they can be passed.
292Under the Federal Tort and Claims Act, patients cannot sue the FDA, but this new waiver would similarly protect hospitals,
doctors, and researchers of dangerous treatments for rare and fatal diseases, like X-SCID.
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